Bayer's Q2 Beat Puts a 61-Euro Target on the Table — But Missouri Still Holds the Pen
Published on 08/05/2026 at 14:12 | Redaktion boerse-global.de
The market's reaction to Bayer's second-quarter numbers has been swift and unambiguous. By Wednesday's session, the shares had climbed 3.55 percent to 50.12 euros, building on a Tuesday gain that took the stock from 48.40 euros into positive territory. That puts the Leverkusen-based group within roughly seven percent of its 52-week high of 53.86 euros, a level touched in early July — just days after the US Supreme Court handed the company a pivotal legal victory.
The catalyst was a set of results that landed comfortably ahead of consensus. Adjusted EBITDA rose 1.9 percent to 2.144 billion euros, beating the Bloomberg-compiled forecast of 1.93 billion euros by a wide margin. Revenue reached 10.872 billion euros, up 2.2 percent on a currency- and portfolio-adjusted basis. Perhaps most striking, the group swung to a net profit of 219 million euros against a 199 million euro loss in the same quarter last year. Adjusted earnings per share, however, slipped 16.7 percent to 0.95 euros — a reminder that the operational turnaround is outpacing the bottom-line recovery on a per-share basis.
Managing risk is at the heart of any successful business — and that extends beyond financial markets to the safety of your own workforce. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace hazards properly and stay compliant. Download the free Risk Assessment Toolkit
Crop Science Carries the Quarter
The engine behind the beat was once again the agriculture division. Crop Science saw operating profit surge 30.2 percent to 902 million euros, with margins reaching 18.4 percent. The division's first-half EBITDA margin came in at 31 percent, helped by firmer glyphosate pricing and the registration of Dicamba. CEO Bill Anderson struck a confident tone, describing the group as operationally on track with all three divisions meeting their plans.
The pharma business painted a more mixed picture. Revenue of 4.46 billion euros masked a sharp divergence within the portfolio: Xarelto sales fell 42 percent and Eylea dropped 33 percent, both casualties of patent expiries and biosimilar competition. Newer products Nubeqa and Kerendia grew strongly, partially offsetting those declines, but the segment's trajectory remains a work in progress.
Debt Falls Faster Than Promised
The balance sheet provided its own source of relief. Bayer has trimmed its net financial debt guidance to 29–30 billion euros, down from the previous 32–33 billion euro range. The improvement stems from the 3 billion euro equity injection tied to the Apollo deal, though net debt stood at 33.647 billion euros as of June 30. The group also placed a 5 billion dollar bond, adding further flexibility. Management reaffirmed the full-year 2026 outlook, targeting currency-adjusted revenue of 45–47 billion euros and adjusted EBITDA of 9.6–10.1 billion euros.
Anderson used the results call to push back against persistent speculation about a potential breakup, insisting the focus remains on the ongoing restructuring around five defined priorities rather than any corporate separation.
The Legal Fog Begins to Lift
The Supreme Court's late-June ruling — that Bayer cannot be compelled to add cancer warnings to Roundup labels — has shifted the risk calculus for investors. The decision strengthens the company's hand in settlement negotiations and has already been reflected in analyst thinking. JPMorgan's Richard Vosser upgraded the stock to "Overweight" and lifted his price target from 50 to 61 euros, arguing that glyphosate risks have become manageable and the business outlook is improving. Deutsche Bank kept its "Buy" rating and 60 euro target, with analyst Virginie Boucher-Ferte noting EBITDA came in roughly 11 percent above consensus. DZ Bank raised its target to 60 euros from 54, UBS sees fair value at 62 euros, while Jefferies remains more cautious with a "Hold" and 46 euro target — though it too acknowledged the revenue and EBITDA beat.
When legal and regulatory scrutiny intensifies, having the right documentation in place makes all the difference. Over 37,000 UK businesses use a free compliance toolkit covering risk assessments, fire safety, and hazardous substances to protect their operations. Get the free Health & Safety Toolkit
The next test arrives on August 19, when a Missouri court hears arguments on a potential settlement framework that could cost up to 7.25 billion dollars over 21 years. For investors, that hearing offers something the company has lacked for years: a concrete, quantifiable path toward resolving the Roundup litigation. The wide dispersion in analyst targets — 46 to 62 euros — reflects lingering disagreement over how to price those legal risks, but the direction of travel is increasingly clear.
The stock has now gained roughly 35 percent since the start of the year, a rally that has been powered by the combination of operational momentum in agriculture and a legal environment that is finally turning favorable. Whether that momentum holds may well depend on what happens in a Missouri courtroom later this month.
